iPSC-derived motor neurons: suppliers, purity and price per million

The short answer: wild-type human iPSC-derived spinal motor neurons list from about $333 to $739 per million cells, and disease-mutation lines carry a premium of roughly 30 to 108 percent over wild type at the same cell count. At least four suppliers publish a price.

The specification that matters most here is not purity. It is whether the matched isogenic control is available on the same lot schedule as the mutant line, because disease-line motor neuron work is worthless without it and the two are stocked separately by every supplier we checked.

The price and specification table

The three findings worth acting on

1. Axol prices every genotype identically

Axol lists unaffected, C9orf72 carrier, ALS C9orf72, ALS TDP-43 and ALS SOD1 motor neurons at $836.00 each, and every corresponding kit at $2,046.00. There is no disease premium at all across five genotypes including three ALS patient lines.

That is unusual and it is a genuine procurement advantage for anyone running a multi-genotype panel. Where iXCells charges $739 for normal and $1,537 for SOD1 A4V homozygous, Axol charges the same number for both categories. Whether Axol’s specific donor lines are the ones your study design needs is a separate question, and the answer to that is not price.

2. bit.bio’s disease premium is 30 percent, and it is flat

bit.bio prices wild-type, GFP-reporter and CRISPRko-ready motor neurons all at the same standard price of 999, and every disease line — SOD-1 G93A homozygous and heterozygous, FUS P525L homozygous and heterozygous, four TDP-43 variants — at 1,299. That is a flat 30 percent premium, applied uniformly, with no variant priced above another.

The engineered backgrounds being free relative to wild type is the more striking part. If your project would otherwise require in-house line engineering to get a GFP reporter or a CRISPR-ready background into motor neurons, that work is priced at zero here.

bit.bio also publishes a volume ladder: 1 to 9 packs at standard price, 10 packs or more with an automatic 10 percent discount, and orders above 100 vials by quote. Academic pricing and bulk pricing are handled through a named orders address rather than the storefront.

3. iXCells prices the isogenic control back at wild-type level

This is the most useful single number on the page for anyone doing disease modelling.

The mutant costs roughly twice the control, and the control costs exactly what a normal line costs. So a properly controlled single-variant experiment at one million cells each is about $2,254, not $739 — a number that is routinely missed at budgeting time because the mutant is the line people price.

The failure mode to avoid: order the mutant, start the differentiation, and then discover the matched control is on a different lot schedule. Disease-line availability in this category is lumpy and unadvertised — a line can be listed and still be weeks or months out. Reserve the mutant and the control together or reserve neither.

Purity: only one supplier publishes a number

This is the honest position, and it is worth stating plainly because the query “ISL1/HB9 purity” is what buyers search for.

bit.bio is the only supplier in the set publishing a numeric threshold: greater than 80 percent of cells express MNX1 (also known as HB9) on day 14, measured by single-cell RNA sequencing. The product page further documents that expression of the key spinal motor neuron marker genes MNX1, FOXP1 and ISL2 is detected in the culture from day 4, and shows bulk RNA-seq PCA, single-cell panels for pan-neuronal, motor and cholinergic markers, immunocytochemistry panels, and mean firing rate data from multielectrode arrays.

That is a subtype-identity claim measured by gene expression on a named marker at a named day, which is the specific form of evidence this cell type requires.

iXCells, Axol and BrainXell publish characterisation data — morphology, marker expression, functional data — without a release threshold. That is not a quality judgement. A supplier with a detailed immunocytochemistry panel and no headline percentage may be telling you more than one with a percentage and nothing else. But if your protocol or your grant requires a stated purity, the field narrows to one supplier immediately.

A note on ISL1 versus HB9. These are not interchangeable. HB9 (MNX1) is the more specific spinal motor neuron marker; ISL1 is expressed in spinal motor neurons but also in other neuronal populations, including cranial motor neurons and some sensory and interneuron populations. A purity figure quoted against ISL1 alone is a weaker claim than the same figure against HB9. When you ask a supplier for purity, ask which marker, and if the answer is ISL1, ask what the HB9 fraction is.

Differentiation route, and why almost nobody discloses it

The route to a motor neuron determines maturation time, subtype fidelity, batch consistency and how the cells behave in co-culture. Three broad approaches are used in the field:

• Transcription-factor programming. Forced expression of motor neuron programme factors, giving fast and highly consistent differentiation. bit.bio’s opti-ox platform is a deterministic cell programming approach of this class, which is consistent with its published day-4 marker onset and day-14 purity figure.
• Small-molecule patterning. Retinoic acid and sonic hedgehog agonist patterning of neural progenitors, the classical developmental route. Slower, with more subtype heterogeneity, but developmentally faithful.
• Hybrid approaches. Programming combined with patterning cues.

Very few suppliers state which they use. The observable proxy is marker timing: a product reaching mature motor neuron marker expression within roughly two weeks of thaw is almost certainly programmed; one requiring four to six weeks of patterning is not. Ask for the day-by-day marker timeline rather than the route name — suppliers answer the first question readily and treat the second as proprietary.

The practical consequence for a buyer: if you are co-culturing motor neurons with myotubes for neuromuscular junction work, the two cultures must reach compatible maturity on compatible media at compatible times. A fast-programmed motor neuron and a four-week myotube differentiation are a scheduling problem before they are a biology problem.

Media is a large and separate line item

Motor neuron media is priced independently by every supplier and it is not a rounding error.

Note the Axol accelerator supplement at $839 for one millilitre — effectively the price of a vial of cells. That single line explains most of the gap between Axol’s $836 cells-only price and its $2,046 kit price, and it is the reason the kit-versus-cells comparison across vendors is meaningless. Axol’s kit bundles a supplement that other vendors do not sell at all.

If the datasheet performance was measured with the accelerator supplement, buying cells without it means buying a product characterised in a condition you will not be running.

Species substitution, where it is legitimate

iXCells lists rat spinal cord motor neurons (10RA-033) at $589.00. Where species is genuinely not a constraint — protocol development, electrode plate qualification, seeding density optimisation, teaching a new technician to plate — the rodent product does the job at a fraction of the cost of burning a $1,537 mutant human vial on a rehearsal.

This is not a substitution for the experiment. It is a substitution for the practice runs, and it is one of the few real cost levers available on disease-line work.

Specification checklist for a motor neuron quote

• Genotype, named precisely: variant, zygosity, and whether a matched isogenic control is required. Confirm both are on the same lot schedule before ordering either.
• Purity specification, and specifically the HB9/MNX1 fraction, not just ISL1.
• Day of culture at which purity is measured. bit.bio states day 14; not every supplier states a day at all.
• Cell count and the counting convention — bit.bio states viable cells explicitly, others state a number without naming the convention.
• Pack size options at the total programme count, not the next experiment. iXCells drops from $739 to $590 per million between the 1M and 4M vial.
• Media and supplement package, priced separately, and whether the datasheet performance depends on it.
• Marker timeline day by day, which is the honest proxy for differentiation route.
• Co-culture intent — if motor neurons are going onto myotubes for NMJ work, state it, because it constrains media compatibility on both sides.
• Whether raw MEA traces are available if network activity matters.
• Licence terms for anything beyond internal research use.

Where to go next

The price-per-million analysis does the normalisation across all neuronal subtypes with the counting conventions stated. The supplier directory and the head-to-head comparison cover more columns of verified supplier data. If the work is cortical rather than spinal, cortical neurons is the equivalent page.

How we can help

Disease-line motor neuron sourcing fails on availability far more often than on price. We check whether the mutant and its matched control are actually in inventory on compatible lot schedules before anyone commits, chase the HB9 purity figure where it is not published, and put the media and supplement lines into the comparison so the totals are real.

Tell us the variant, the control requirement, the count and the delivery date. If a catalogue line is the right answer we will say so.